Menu Search
Equities

Oncozenge AB

8LY:FRA

Oncozenge AB

Actions
  • Price (EUR)0.775
  • Today's Change-0.041 / -5.02%
  • Shares traded1.44k
  • 1 Year change+234.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 07:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-11.78m
  • Incorporated2020
  • Employees--
  • Location
    Oncozenge ABGustavslundsvagen 34BROMMA 167 51SwedenSWE
  • Phone+46 8311420
  • Websitehttps://oncozenge.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.